(Q36052183)

11 August 2017

1 reference

title

Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club (English)

1 reference

postmenopausal osteoporosis

11 August 2017

0 references

1 reference

8

Jean-Yves Reginster

1 reference

11 August 2017

7

Serge Rozenberg

1 reference

11 August 2017

6

Jean-Marc Kaufman

1 reference

11 August 2017

5

Stefan Goemaere

1 reference

11 August 2017

2

Jean-Jacques Body

1 reference

11 August 2017

Jean-Pierre Devogelaer

series ordinal

4

object named as

Jean-Pierre Devogelaer

1 reference

11 August 2017

1

Steven Boonen

1 reference

11 August 2017

3

Yves Boutsen

1 reference

11 August 2017

language of work or name

English

0 references

publication date

26 January 2005

1 reference

Osteoporosis International

11 August 2017

published in

1 reference

11 August 2017

volume

16

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

239-254

1 reference

Risk factors for hip fracture in men. Hip Fracture Study Group

11 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-004-1812-1

Osteoporosis prevention with sex hormone replacement therapy

21 January 2018

1 reference

12 December 2020

Stronger back muscles reduce the incidence of vertebral fractures: a prospective 10 year follow-up of postmenopausal women

1 reference

12 December 2020

Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group

1 reference

12 December 2020

Bone mass and structure are enhanced following a 2-year randomized controlled trial of exercise in prepubertal boys

1 reference

12 December 2020

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

1 reference

12 December 2020

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial

1 reference

12 December 2020

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial

1 reference

12 December 2020

Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture

1 reference

12 December 2020

Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial

1 reference

12 December 2020

Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer

1 reference

12 December 2020

[Involutional osteoporosis in women: therapeutic strategy. Recommendations of the Belgian Bone Club].

1 reference

12 December 2020

Apparent beneficial effects of tamoxifen on bone mineral content in patients with breast cancer: Preliminary study

1 reference

12 December 2020

Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study

1 reference

12 December 2020

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis

1 reference

12 December 2020

Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis

1 reference

12 December 2020

Esophagitis associated with the use of alendronate

1 reference

12 December 2020

NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Determinants of peak bone mass: clinical and genetic analyses in a young female Canadian cohort

1 reference

12 December 2020

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

1 reference

12 December 2020

Detection of collagenase mRNA in odontoclasts of bovine root-resorbing tissue by in situ hybridization

1 reference

12 December 2020

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

12 December 2020

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

1 reference

12 December 2020

Climacteric medicine: European Menopause and Andropause Society (EMAS) statements on postmenopausal hormonal therapy

1 reference

12 December 2020

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

12 December 2020

Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trial

1 reference

12 December 2020

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

12 December 2020

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

1 reference

12 December 2020

Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis

1 reference

12 December 2020

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

12 December 2020

Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial

1 reference

12 December 2020

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

1 reference

12 December 2020

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

12 December 2020

Randomised controlled trial of hip protectors for the prevention of second hip fractures

1 reference

12 December 2020

Prevention of Hip Fractures by External Hip Protectors

1 reference

12 December 2020

Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial

1 reference

12 December 2020

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Risedronate prevents new vertebral fractures in postmenopausal women at high risk

1 reference

12 December 2020

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

1 reference

12 December 2020

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

1 reference

12 December 2020

Relationship between physical activity and bone mineral status in young adults: the Northern Ireland Young Hearts Project.

1 reference

12 December 2020

Bone mineral density and total body bone mineral content in 18- to 22-year-old women

1 reference

12 December 2020

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study

1 reference

12 December 2020

Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes

1 reference

12 December 2020

Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin

1 reference

12 December 2020

Preventing injuries in older people by preventing falls: a meta-analysis of individual-level data

1 reference

12 December 2020

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups

1 reference

12 December 2020

The effect of a specific strength-development exercise on bone mineral density in perimenopausal and postmenopausal women.

1 reference

12 December 2020

Prevention of hip fracture in elderly people with use of a hip protector

1 reference

12 December 2020

Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial

1 reference

12 December 2020

Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

1 reference

12 December 2020

Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women

1 reference

12 December 2020

Effect of discontinuation of alendronate treatment and exercise on bone mass and physical fitness: 15-month follow-up of a randomized, controlled trial

1 reference

12 December 2020

Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women.

1 reference

12 December 2020

Future horizons for calcitonin: a U.S. perspective

1 reference

12 December 2020

Consensus Development Conference on Osteoporosis. Hong Kong, April 1-2, 1993

1 reference

12 December 2020

1 reference

12 December 2020

Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study

1 reference

12 December 2020

Nonpharmacological prevention of osteoporotic fractures

1 reference

12 December 2020

Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women

1 reference

12 December 2020

Physical activity, muscle strength, and calcium intake in fracture of the proximal femur in Britain

1 reference

12 December 2020

Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial

1 reference

12 December 2020

Vitamin D3 and calcium to prevent hip fractures in elderly women

1 reference

12 December 2020

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Dietary protein intake and risk of osteoporotic hip fracture in elderly residents of Utah

1 reference

12 December 2020

Costs Induced by Hip Fractures: A Prospective Controlled Study in Belgium

1 reference

12 December 2020

Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis

1 reference

12 December 2020

Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial

1 reference

12 December 2020

Parathyroid hormone in the treatment of involutional osteoporosis: back to the future.

1 reference

12 December 2020

Effect of calcitonin on bone mass and fracture rates

1 reference

12 December 2020

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

1 reference

12 December 2020

Soy isoflavone supplementation in postmenopausal women. Effects on plasma lipids, antioxidant enzyme activities and bone density.

1 reference

12 December 2020

Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial

1 reference

12 December 2020

Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.

1 reference

12 December 2020

1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin

1 reference

12 December 2020

Nutrition in orthopaedic surgery

1 reference

12 December 2020

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

1 reference

12 December 2020

Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.

1 reference

12 December 2020

Prevention and treatment of postmenopausal osteoporosis. National Consensus of the "Belgian Bone Club", November 1996.

1 reference

12 December 2020

Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial

1 reference

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

12 December 2020

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

12 December 2020

Characteristics of falls and risk of hip fracture in elderly men.

1 reference

12 December 2020

Annual injection of vitamin D and fractures of aged bones.

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

12 December 2020

Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation

1 reference

12 December 2020

Effect of Dietary Protein on Bone Loss in Elderly Men and Women: The Framingham Osteoporosis Study

1 reference

12 December 2020

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

1 reference

12 December 2020

Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study

1 reference

12 December 2020

Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial

1 reference

12 December 2020

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

1 reference

12 December 2020

Parathyroid Hormone plus Alendronate — A Combination That Does Not Add Up

1 reference

12 December 2020

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

1 reference

12 December 2020

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

12 December 2020

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

10.1007/S00198-004-1812-1

Identifiers

DOI

1 reference

release_gthwhjcadvfr5bjqw3dskrymuy

11 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gthwhjcadvfr5bjqw3dskrymuy

24 November 2022

mapped directly with Wikidata item

1 reference